Treatment of hepatitis C in patients with haemophilia - The Israeli National Hemophilia Center experience

Haemophilia

Volumn 14, Issue 2, 2008, Pages 336-342

  Maor, Yaakov ^a   Schapiro, J M ^a   Bashari, D ^a   Lurie, Y ^b   Safadi, R ^c   Segol, O ^d   Paritsky, M ^e   Rachlis, Z ^e   Avidan, B ^a   Bar meir, S ^a   Martinowitz, U ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d CARMEL MEDICAL CENTER   (Israel)

^e HAEMEK MEDICAL CENTER   (Israel)

Author keywords

Anaemia, haemophilia; Hepatitis C; Pegylated interferon; Ribavirin; Viral response

Indexed keywords

DIDANOSINE; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; SEROTONIN UPTAKE INHIBITOR; ZIDOVUDINE;

ABDOMINAL BLEEDING; ADULT; ANEMIA; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BONE MARROW DEPRESSION; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; COHORT ANALYSIS; COUGHING; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FLU LIKE SYNDROME; GENOTYPE; HEMATOMA; HEMOPHILIA; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; INJECTION SITE REACTION; IRRITABILITY; ISRAEL; LACTATE BLOOD LEVEL; NEUTROPENIA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; THROMBOCYTOPENIA; WEIGHT REDUCTION;

ADULT; ANEMIA; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEMOPHILIA A; HEMORRHAGE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; ISRAEL; LIVER; MIDDLE AGED; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 40349098616     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2007.01633.x     Document Type: Article

References (27)

1. Mannucci PM, Colombo M. Virucidal treatment of clotting factor concentrates. Lancet 1988; 2: 782-5.
2. Fried MW. Management of hepatitis C in the hemophilia patient. Am J Med 1999; 107 (Suppl): 85-9.
3. Lee C, Dusheiko G. The natural history and antiviral treatment of hepatitis C in Haemophilia. Haemophilia 2002; 8: 322-9.
4. Yee TT, Griffioen A, Sabin CA, Dusheiko G, Lee CA. The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985. Gut 2000; 47: 845-51.
5. Goedert JJ, Eyster E, Lederman MM et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 2002; 100: 1584-9.
6. Fried MW, Peter J, Hoots K et al. Hepatitis C in adults and adolescents with hemophilia: A randomized, controlled trial of interferon alfa-2b and ribavirin. Hepatology 2002; 36: 967-72.
7. Posthouwer D, Mauser-Bunschoten EP, Fischer K, Makris M. Treatment of chronic hepatitis C in patients with haemophilia: A review of the literature. Haemophilia 2006; 12: 473-8.
8. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958-65.
9. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
10. Chung RT, Andersen J, Volberding P et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451-9.
11. Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-50.
12. Carrat F, Bani-Sadr F, Pol S et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: A randomized controlled trial. JAMA 2004; 292: 2839-48.
13. Mancuso ME, Rumi MG, Santagostino E et al. High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C. Haematologica 2006; 91: 1367-71.
14. Shire NJ, Horn PS, Rouster SD et al. HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia. Hepatology 2006; 44: 1146-57.
15. Posthouwer D, Fischer K, De Heusden N, Mauser-Bunschoten EP. Pegylated interferon and ribavirin combination therapy for chronic hepatitis C in patients with congenital bleeding disorders: A single-centre experience. Haemophilia 2007; 13: 98-103.
16. Zhang M, Rosenberg PS, Brown DL et al. Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia. Blood 2006; 107: 892-7.
17. Fried MW, Kroner BL, Preiss LR, Wilhelmsen K, Goedert JJ, Multicenter Hemophilia Cohort Study. Hemophilic siblings with chronic hepatitis C: familial aggregation of spontaneous and treatment-related viral clearance. Gastroenterology 2006; 131: 57-64.
18. Imbert-Bismut F, Ratziu V, Pieroni L et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study. Lancet 2001; 357: 1069-75.
19. Poynard T. Diagnosis Method of Inflammatory or Cancerous Disease Using the Biochemical Markers. United States 2003. Patent No US 6,631,330 B1.
20. Gerken G, Rothaar T, Rumi MG et al. Performance of the Cobas Amplicor HCV Monitor test, version 2.0, an automated reverse transcription-PCR quantitative system for hepatitis C virus load determination. J Clin Microbiol 2000; 38: 2210-4.
21. Halfon P, Trimoulet P, Bourlière M et al. Hepatitis C virus genotyping based on 5′ noncoding sequence analysis (Trugene). J Clin Microbiol 2001; 39: 1771-3.
22. Ferenci P, Fried MW, Shiffman ML et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin. J Hepatol 2005; 43: 425-33.
23. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006; 130: 231-64.
24. Halfon P, Bourlière M, Deydier R et al. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: The Fibropaca study. Am J Gastroenterol 2006; 101: 547-55.
25. Maor Y, Bashari D, Kenet G et al. Non-invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: Can you avoid liver biopsy? Haemophilia 2006; 12: 372-9.
26. Berg T, von Wagner M, Nasser S et al. Extended treatment duration for hepatitis C virus type 1: Comparing 48 versus 72weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130: 1086-97.
27. Afdhal NH, Dieterich DT, Pockros PJ et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized controlled study. Gastroenterology 2004; 126: 1302-11.